Tonix Pharmaceuticals Holding Corp. (TNXP)
2024-09-30 | 2024-06-30 | |||
|---|---|---|---|---|
| Revenue | 2,822 | 2,208 | ||
| Asset impairment charges | - | 58,957 | ||
| Selling, general and administrative | 7,707 | 7,502 | ||
| Research and development | 9,114 | 9,698 | ||
| Cost of revenue | 1,555 | 3,367 | ||
| Costs and expenses | 18,376 | 79,524 | ||
| Operating income (loss) | -15,554 | -77,316 | ||
| Grant income | 1,668 | - | ||
| Other (expense) income, net | -327 | -605 | ||
| Fair value - mark to market adjustment | - | 855 | ||
| Net income (loss) available to common stockholders, basic | -14,213 | -78,776 | ||
| Basic eps | -0.23 | -19.28 | ||
| Diluted eps | -0.23 | -19.28 | ||
| Basic average shares | 62,122,283 | 4,085,132 | ||
| Diluted average shares | 62,122,283 | 4,085,132 | ||